Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Buparlisib (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms Bubble
  • Most Recent Events

    • 04 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.
    • 08 Mar 2016 Planned initiation date changed from 1 Jun 2015 to 1 Apr 2016 as per ISRCTN: Current Controlled Trials record.
    • 08 Mar 2016 Status changed from recruiting to not yet recruiting as per ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top